

Agenda

MOC na ASCO 2023



PRÓSTATA

Daniel Vargas P. de Almeida



MOC na ASCO 2023

- Oncologista Clínico do Grupo Oncoclínicas de Brasília, DF. Ex-Residente Chefe da BP – A Beneficência Portuguesa de São Paulo. Editor do portal MOC Notícias. *Research Fellow* em Oncologia Geniturinária no *Memorial Sloan-Kettering Cancer Center*, em Nova Iorque.
- CRM 27574-DF.

Conflitos de Interesse



MOC na ASCO 2023

De acordo com a Norma 1595/2000 do Conselho Federal de Medicina e com a RDC 96/2008 da ANVISA, declaro:

- Participação como palestrante de eventos patrocinados pelas empresas: Astellas, AstraZeneca, Bayer, Eli Lilly, Ipsen, Libbs, Janssen-Cilag, Sanofi-Aventis e Zodiac.
- *Advisory board*: AstraZeneca e Zodiac.
- Declaro não possuir ações de nenhuma das companhias acima listadas.



Oral abstract session:

- **LBA5000:** Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.

Oral abstract session:

- **Abstr 5004:** TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.



Oral abstract session:

- **Abstr 5005:** LuPARP: Phase 1 trial of ¹⁷⁷Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).

Poster session

- **Abstr 5087:** Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.



Poster session:

- **Abstr 5025:** Prostate cancer public health system database from Brazil: Racial disparities and heterogeneity of treatment interventions to understand evidence-based practice patterns in a large real-world database.

Poster discussion

- **Abstr 5019:** Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC).



Poster discussion

- **Abstr 5009:** PSMA PET guided salvage radiotherapy among patients with prostate cancer in the post-prostatectomy setting: A single center post-hoc analysis.

Poster discussion

- **Abstr 5018:** Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T.



Poster discussion

- **Abstr 3017:** ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor.

Education session

- Management of Prostate Cancer in Older Adults.

Créditos

MOC na ASCO 2023 © 2023 MOC - Manual de Oncologia Clínica do Brasil. Todos os direitos reservados. São Paulo, SP.
Proibida a reprodução total ou parcial do conteúdo e imagens sem a permissão dos titulares de seus direitos autorais.

Apoio educacional:

